Published Year: 2023
Asia-Pacific and Middle East NGS Market: Focus on Offering, Platform, Throughput, Technology Type, A
The Asia-Pacific and Middle East NGS market was valued at $1,055.6 million in 2022 and is...
Market Research Report
A quick peek into the report
Market Report Coverage
 Market.png)
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.
The top segment players who are leading include manufacturers of Next Generation Sequencing equipment and consumables, which captured around 61.53% of the presence in the market in 2022. The NGS services (relating to servicing and maintenance of the NGS equipment) accounted for approximately 38.47% of the presence in the market in 2022.
Key Companies Profiled:
• BGI Group
• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• Pacific Biosciences of California, Inc.
• Oxford Nanopore Technologies plc.
• Agilent Technologies, Inc.
• Qiagen N.V.
• Pillar Biosciences
• Burning Rock Biotech Limited
• Singular Genomics Systems, Inc.
• DANAHER CORPORATION
• F. Hoffmann-La Roche Ltd
• Twist Bioscience Corporation
• Revvity, Inc.
• Centogene N.V.
Next Generation Sequencing (NGS) Industry and Technology Overview
 Market.png)
The global NGS market was valued at $6.76 billion in 2022 and is expected to reach $28.47 billion by 2033, growing at a CAGR of 13.97% during the forecast period 2023-2033. The key factors driving the growth of the global Next Generation Sequencing market include the decreasing cost of genome sequencing, the potential of NGS in the field of oncology, the growing number of population-wide genomic studies, rising government initiatives to support the advancement and integration of NGS in healthcare, and advantages of NGS technology over other technologies.
Market Introduction
NGS has been the backbone of the genomic revolution over the last decade, demonstrating promise in a variety of scientific fields. It is a high-throughput method that allows for the quick sequencing of base pairs of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). The NGS technique has revolutionized genomic research and is now making its way into the clinical setting as well.
The next-generation sequencing workflow contains four basic steps, i.e., data extraction, library preparation, sequencing, and data analysis. The report only considers products falling under the library preparation and sequencing steps.
Library Preparation: The library preparation step prepares DNA or RNA samples to be compatible with a sequencer. Sequencing libraries are typically created by fragmenting DNA and adding specialized adapters to both ends. DNA fragments can then be amplified and purified.
Sequencing: During the sequencing step of the NGS workflow, libraries are loaded onto a flow cell and placed on the sequencer. The clusters of DNA fragments are amplified in a process called cluster generation, which results in millions of copies of single-stranded DNA. The sequences are then read one by one.
Industrial Impact
NGS has made an impact in the following ways:
Biomedical and Clinical Research: NGS has revolutionized genomics research, enabling scientists to study the genetic basis of diseases, identify disease-causing variants, and develop targeted therapies. It has facilitated the discovery of novel biomarkers, personalized medicine approaches, and advancements in precision oncology and rare disease diagnosis.
Pharmaceutical and Drug Development: NGS plays a vital role in drug discovery and development. It facilitates target identification, validation, and optimization in the early stages of drug development. NGS is also used in pharmacogenomics to predict drug responses and potential adverse effects based on an individual's genetic profile.
Microbiology and Infectious Disease Surveillance: NGS has transformed microbiology by enabling the rapid identification and characterization of microbial pathogens. It aids in the surveillance of infectious diseases, monitoring antimicrobial resistance, and studying outbreaks by sequencing pathogen genomes and identifying transmission patterns.
Forensics and Human Identification: NGS has enhanced forensic DNA analysis and human identification. It allows for the identification of individuals from trace amounts of DNA, complex DNA mixtures, and degraded samples. NGS technologies have increased the resolution and accuracy of DNA profiling, aiding criminal investigations and paternity testing.
Impact of COVID-19
NGS has played a crucial role in the genomic surveillance of SARS-CoV-2, the virus responsible for COVID-19. Sequencing the viral genome has helped in tracking the spread of different variants and understanding their genetic characteristics, which has been essential for public health efforts, vaccine development, and treatment strategies. NGS has been employed in studies investigating the genetic susceptibility to COVID-19 and its severity. By sequencing the genomes of affected individuals, researchers have sought to identify genetic variations associated with the risk of infection, disease progression, and response to treatment.
The global supply chain for NGS instruments, consumables, and reagents experienced severe disruptions due to the pandemic. Manufacturing and shipping delays impacted the availability of NGS products and tests, especially in developing regions such as the Middle East, Africa, and Rest-of-the-World.
Market Segmentation:
Segmentation 1: by Offering
• Consumables
o Library Preparation Kits
o Sequencing Kits
• Equipment
• Services
Consumables to Continue Dominating the Next Generation Sequencing Market (by Offering)
Consumables comprise NGS kits, reagents, and gene panels, used for the sequencing part of the NGS workflow. NGS kits and reagents primarily consist of library preparation kits and sequencing kits, as explained below:
Library Preparation Kits: Library preparation is the first step of the NGS workflow and involves fragmentation of DNA followed by end repair, the adaption of adapters, and the optional PCR amplification. Library preparation can be either performed by the ligation-based method or by amplicon sequencing. Several players in the global NGS market offer kits for library preparation, barcoding, clonal amplification, and target enrichment, among others.
NGS Kits (or Sequencing Kits): These contain reagents and enzymes for the final sequencing step of the NGS workflow. This segment also consists of NGS-based panel/assay kits that employ targeted sequencing to only target specific regions of the genome expected to contain gene mutations. Some panels may target a small set of genes that are known to be associated with a particular disease, while others may target a broader set of genes or genomic regions to enable more comprehensive profiling.
The offering segment also consists of equipment. The equipment segment in the global Next Generation Sequencing market comprises next-generation sequencing instruments required for sequencing genomic samples of various research and diagnostics fields. NGS equipment can be of different throughputs ranging from low- to high throughput based on their applications for different end users. While NGS platforms hold immense potential for a wide range of research and clinical applications, the high capital investment is one of the key factors hindering the adoption of NGS equipment.
Lastly, the services segment includes services related to the maintenance and servicing of the sequencers as provided by manufacturers of NGS platforms.
Segmentation 2: by Company
• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• Pacific BioSciences of California, Inc.
• Oxford Nanopore Technologies plc.
• Other Companies
Illumina, Inc. to Dominate the Global NGS Market (by Company)
Illumina, Inc. has been dominating the Next Generation Sequencing market for a long time and holds the largest market share currently, followed by Thermo Fisher Scientific Inc.
Segmentation 3: by Throughput
• High- and Ultra-High-Throughput
• Medium-Throughput
• Low-Throughput
High- and Ultra-High Throughput Segment to Dominate the Global Next Generation Sequencing Market (by Throughput)
High throughput is essential because it enables the analysis of a large number of samples simultaneously, allowing for efficient processing and cost-effective sequencing. It allows researchers to perform comprehensive genome-wide analysis, detect rare genetic variants, and gain a deeper understanding of genetic variations, gene expression, and epigenetic modifications. High-throughput Next Generation Sequencing is particularly valuable in research, clinical, and agricultural settings where large-scale studies and high sample throughput are necessary for making significant discoveries and advancements.
Segmentation 4: by Technology Type
• Sequencing by Synthesis
• In Torrent Semiconductor Sequencing
• Single Molecule Real-Time Sequencing
• Nanopore Sequencing Technology
• Other Technologies
SMRT Sequencing and Nanopore Sequencing to Register Maximum Growth in the Market
Sequencing by Synthesis (SBS): It is a widely adopted next-generation sequencing (NGS) technology. It sequences tens of millions of parallel clusters on the flow cell surface using four fluorescently tagged nucleotides. During each sequencing cycle, a single tagged deoxynucleotide triphosphate (dNTP) is added to the nucleic acid chain. The majority of Illumina, Inc.'s equipment, such as the iSeq, MiniSeq, and NextSeq 550 systems, are based on the SBS technology.
Ion Torrent Semiconductor Sequencing: This technology leverages the methods of synthesis-based sequencing technologies. Ion torrent semiconductor sequencing is based on the use of basic chemistry and unique semiconductor technology. Thermo Fisher Scientific Inc. is the sole manufacturer of ion torrent sequencing systems.
Single-Molecule Real-Time (SMRT) Sequencing: It is the core technology generating long-read sequencing platforms. This technology utilizes zero-mode waveguides (ZMWs) that are tiny chambers of nanometer dimensions made of thin metal film and have a glass substrate at the bottom. Each smart cell contains millions of such chambers or ZMWs, in which the polymerization and sequencing reactions occur. Pacific Biosciences of California utilizes SMRT technology in its Sequel II/IIe platforms.
Nanopore Sequencing Technology: It relies on measuring the changes in electrical current as the DNA molecule passes through the nanopore, which is caused by the different chemical structures of the bases (A, C, G, T) in the DNA molecule. Nanopore sequencing can generate long read lengths, making it well-suited for applications such as genome assembly and structural variant detection. The technology is offered by Oxford Nanopore Technologies plc., for instance, in its MinION and GridION systems.
Segmentation 5: by Sequencing
• Whole Genome Sequencing
• Whole Exome Sequencing
• Targeted Sequencing
Targeted Sequencing Segment: Highest share in the market due to low cost and in-depth sequencing of targeted regions
Whole Genome Sequencing (WGS): It refers to sequencing the entire genome of an organism using NGS. Decreasing costs of genomic sequencing in developed countries and the availability of several cloud-based software solutions to manage large amounts of data are the key factors driving the growth of this segment.
Whole Exome Sequencing (WES): It is a cost-effective alternative to WGS in cases where WGS is unnecessary or impractical. It analyzes only the protein-coding regions of the genome called exons that makeup around 1-2% of the entire genome.
Targeted Sequencing: It enables in-depth sequencing of particular genes of interest and is a useful tool to identify rare variants. It is used most commonly in clinical settings to aid in the diagnosis of diseases.
Segmentation 6: by Application
• Clinical Diagnostics
o Oncology
o Non-Oncology
• Research
o Oncology
o Non-Oncology
Transition of NGS to Clinical Diagnostics to Take Place Rapidly in the Coming Years
The global NGS market was led by the research segment, with a share of 77.03% in 2022, owing to NGS not being recognized as the standard of care by healthcare providers in several countries worldwide. Furthermore, within further sub-segmentation, the oncology segment held a share of 34.82% in 2022, owing to the growing prevalence of cancer and the various applications of NGS in oncology.
In clinical settings, NGS plays a key role in the diagnosis of various genetic diseases, cancer genomics and precision oncology, pharmacogenomics, and prenatal testing, among others. This is because Next Generation Sequencing enables the simultaneous sequencing of multiple genes associated with a particular condition, facilitating the identification of disease-causing mutations or variants. It helps in identifying somatic mutations, gene fusions, and copy number variations in tumor samples, enabling personalized treatment decisions and targeted therapies.
In research settings, Next Generation Sequencing plays a key role in the genomic discovery, population genomics and evolutionary studies, functional genomics and epigenetics, and microbiome studies.
Segmentation 7: by End User
• Academic and Research Institutes
• Clinical Laboratories
• Pharmaceutical and Biotechnology Companies
• Other End Users
The global Next Generation Sequencing market (by end user) is expected to be dominated by the academic and research insitutes segment.
Segmentation 8: by Country
• North America - U.S., Canada
• Europe - Germany, U.K., France, Italy, Spain, and Rest-of-Europe
• Asia-Pacific - Japan, India, China, South Korea, Australia, Singapore, New Zealand, and Rest-of-Asia-Pacific
• Middle East - U.A.E., K.S.A., Israel, Rest-of-Middle East
• Rest-of-the-World - Latin America, Rest-of-Rest-of-the-World
*Note: Each country is further segmented by offering, equipment (units), and company.
Recent Developments in the Global NGS Market
• In April 2023, NGeneBio signed a business agreement with Agilent Technologies, Inc.’s Korea-based subsidiary, to expand the NGS precision diagnosis in South Korea and abroad.
• In March 2023, Sophia Genetics partnered with Agilent Technologies Inc. to integrate its Sophia DDM Platform with Agilent Technologies Inc.’s research-use-only SureSelect Cancer Comprehensive Genomic Profiling (CGP) assay kit.
• In March 2023, Thermo Fisher Scientific Inc. collaborated with Pfizer to expand access to NGS-based lung and breast cancer testing in more than 30 countries.
• In January 2023, Qiagen N.V. completed the acquisition of Verogen, Inc. in order to deploy next-generation biometrics for forensic and molecular testing.
• In October 2022, Pacific Biosciences of California, Inc. introduced two new sequencing systems, namely, Revio and Onso.
• In September 2022, Illumina, Inc. introduced the first FDA-registered and CE-marked in vitro diagnostic (IVD) high-throughput sequencer, the NovaSeq 6000 Dx. The NovaSeq 6000 Dx is a versatile platform that provides the greatest levels of compliance while also delivering useful insights for patient care.
Demand - Drivers and Limitations
Market Demand Drivers:
Decreasing Cost of Genome Sequencing: The cost of sequencing was over $100.0 million in 2001. However, advancements in sequencing techniques led to a decline in costs, as genome sequencing cost only around $1,000 in 2021. Therefore, as NGS becomes more affordable and accessible to the public, healthcare institutions such as hospitals and clinics, pharmaceutical and biotechnology companies, and academic institutions are expected to pursue NGS testing with vigor.
Potential of NGS in the Field of Oncology Research and as a Companion Diagnostic for Oncology in Clinical Settings: With the rising prevalence of cancer globally coupled with the potential of NGS to assist in the early diagnosis and treatment of cancer, NGS is expected to play an instrumental role in the field of oncology.
Growing Number of Population-Wide Sequencing Studies and Government Initiatives to Integrate NGS in Healthcare: Population-scale sequencing holds significant promise due to its ability to enable an unbiased and extensive study of the human genome and understand the variation among various population types. Population-scale databases integrated with clinical data can reduce the anxiety and stress that patients undergo during a series of testing to confirm the diagnosis. Genomic sequencing studies are also being increasingly undertaken in other emerging countries in Latin America and the Middle East in an effort to better understand the genomes of the local population.
Advantages of NGS Technology over Other Technologies: NGS is a massively parallel sequencing technology that has revolutionized the field of genomics. It has several advantages over other conventional technologies. For instance, while both qPCR and NGS are capable of identifying variants, NGS has a significantly higher discovery power due to its ability to identify novel sequences without the need for any prior knowledge. Moreover, NGS has higher sensitivity to quantity rare variants.
Market Challenges:
Concerns Surrounding the Privacy of Patient Genomic Data: Striking a balance between sharing data for scientific exploration and research while also maintaining the privacy of the participant’s data is tricky and is one of the key challenges that might restrain the growth of the market. The complication with NGS data arises due to the enormous amount of genomic data generated during sequencing, which needs to be deployed on the cloud for easy storage. Cloud-based infrastructure can be accessed easily anywhere, thereby leading to concerns surrounding data protection.
Lack of Complete Reimbursement Coverage for NGS Testing: The lack of “medical necessity” is one of the key reasons behind payers being unwilling to reimburse genetic tests such as Next Generation Sequencing. Large healthcare institutions in the U.S., such as Intermountain Healthcare and Providence St Joseph Health System, have also reported irregular reimbursement for genetic testing from private payers. The reimbursement situation in Europe is also poor, and disparities are present across different countries in the region.
Market Opportunities:
Evolving Regulatory Landscape for Clinical NGS: The evolving regulatory landscape is aimed at reducing the time to commercialize NGS tests. For instance, in 2017, the FDA and CMS jointly established and implemented a novel process to define a regulatory pathway for the approval and clearance of clinical NGS assays. The CMS-FDA Parallel Review Program would enable both organizations to simultaneously review the Next Generation Sequencing test and reduce the time between the FDA approval and CMS’s decision to provide coverage to the Next Generation Sequencing assay.
Growing Number of Gene Mutations across Various Diseases: The growing prevalence of chronic diseases is also accompanied by the growing number of genetic mutations characterizing different diseases. Therefore, the growing number of mutations witnessed across different diseases presents an opportunity for Next Generation Sequencing techniques to interrogate each of these mutations in a single test without the need to obtain more tissue through biopsies.
Analyst’s View
According to Swati Sood, Principal Analyst – BIS Research, “With the growing applications of NGS in healthcare, such as the diagnosis of diseases and technological advancements in NGS platforms, the adoption of Next Generation Sequencing equipment and consumables is expected to increase globally. The Asia-Pacific Next Generation Sequencing market, particularly, is expected to register significant growth during the forecast period 2023-2033.”
Next Generation Sequencing (NGS) Market - A Global and Regional Analysis
Focus on Offering, Company, Throughput, Technology Type, Sequencing, Application, End User, and Country Analysis - Analysis and Forecast, 2023-2033
Some Faq's
Frequently Asked Questions
Next generation sequencing (NGS) is a high-throughput method used to determine a portion of the nucleotide sequence of an individual’s genome. This technique utilizes DNA sequencing technologies that are capable of processing multiple DNA sequences in parallel. According to BIS Research, NGS products consist of consumables, equipment (NGS platforms), and services offered by various genome sequencing companies.
Synergistic activities and product launches/approvals accounted for the maximum number of key developments, i.e., nearly 85% of the total developments in the global NGS market. Key players such as Illumina, Inc. and Thermo Fisher Scientific Inc. are involved in launching new technologically advanced NGS platforms and engaging in synergistic partnerships to gain further market share.
• Supply chain analysis
• Impact of COVID-19
• Emerging NGS technologies
• Primary insights
• Pricing analysis
• Volume of key NGS equipment available in the global NGS market
• Region-level market segmentation by offering, company, throughput, technology, sequencing, end user, and application
• Country-level market segmentation by company and offerings
Genomic sequencing and life science companies, as well as startups looking to enter the NGS market, should buy this report.
Similar Product
You may also like
Published Year: 2022
NGS Sample Preparation Market - A Global and Regional Analysis: Focus on Product, Workflow, Therapeu
The global NGS sample preparation market is projected to reach $3,279.3 million by 2026,...